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Mitochondria are key organelles in eukaryotic evolution that perform crucial roles
as metabolic and cellular signaling hubs. Mitochondrial function and dysfunction are
associated with a range of diseases, including cancer. Mitochondria support cancer
cell proliferation through biosynthetic reactions and their role in signaling, and can
also promote tumorigenesis via processes such as the production of reactive oxygen
species (ROS). The advent of (nuclear) genome-wide CRISPR-Cas9 deletion screens
has provided gene-level resolution of the requirement of nuclear-encoded mitochondrial
genes (NEMGs) for cancer cell viability (essentiality). More recently, it has become
apparent that the essentiality of NEMGs is highly dependent on the cancer cell context.
In particular, key tumor microenvironmental factors such as hypoxia, and changes in
nutrient (e.g., glucose) availability, significantly influence the essentiality of NEMGs. In this
mini-review we will discuss recent advances in our understanding of the contribution of
NEMGs to cancer from CRISPR-Cas9 deletion screens, and discuss emerging concepts
surrounding the context-dependent nature of mitochondrial gene essentiality.
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MITOCHONDRIA AND CANCER
Mitochondria are thought to have arisen from the endosymbiotic fusion of a protobacterium that
had evolved the ability to generate chemical energy through oxidative phosphorylation (OXPHOS),
and an archaeal host cell (Andersson et al., 1998; Fitzpatrick et al., 2006). Over evolutionary time,
mitochondria have become centrally embedded in eukaryotic cell biology, from a physical, genetic,
and functional point of view. Indeed, mitochondria now play host to an array of biochemical
reactions and pathways that support cell viability, and influence survival beyond the bioenergetic
role of OXPHOS. In cancer, the preponderance of studies show that many of the metabolic
pathways and metabolites found in mitochondria play a central role in promoting tumor growth
and disease progression. For example, it has been shown that OXPHOS-dependent mitochondrial
metabolism is pivotal for the availability of amino acids to support biomass accumulation in
proliferating cells, particularly the synthesis of aspartate (Birsoy et al., 2015; Sullivan et al., 2015).
Moreover, mitochondria are important sources of precursors for nucleotide synthesis, such as
folate, which is required for de novo purine and pyrimidine synthesis pathways (Garrow et al., 1993;
Morscher et al., 2018). In addition, the mitochondrial IMS is the site of an OXPHOS-linked step
in the uridine salvage pathway (Loffler et al., 1997), and key components of the redox-regulated
import disulfide relay system within the mitochondrial IMS have been shown to regulate tumor
growth (Yang et al., 2012; Hangen et al., 2015; Al-Habib and Ashcroft, 2021). Furthermore, lipid
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metabolism is dependent on mitochondrial function, both
through catabolism to generate ATP via β-oxidation of fatty
acids (Houten and Wanders, 2010), as well as anabolism to
generate precursors of fatty acids (DeBerardinis et al., 2007; Wise
et al., 2011), steroids (Miller, 2011), and phospholipids (Osman
et al., 2011). Aside from the synthesis of ATP and precursors
for biomass accumulation, mitochondria are the site of many
other biochemical pathways that are critical for supporting tumor
cell viability, such as the detoxification of exogenous bioactive
molecules, heme biosynthesis, and carbonic acid metabolism
(Thomas et al., 2021). Mitochondria as key signaling organelles,
provide important regulation of calcium homeostasis (Giorgi
et al., 2018), and are a source of ROS generation (Shadel and
Horvath, 2015), both of which are known to influence a range
of disease phenotypes in cancer (Sabharwal and Schumacker,
2014; Liu et al., 2020; Perillo et al., 2020). Beyond the
role of mitochondria in supporting cancer cell proliferation,
upregulation of mitochondrial biogenesis has been identified
as a key driver of invasion and metastasis in breast cancer
(LeBleu et al., 2014). Along with performing essential functions
that support proliferation and survival, mitochondria are also
involved in promoting several distinct forms of cell death. These
include apoptosis, involving the cytoplasmic release of molecules
from the mitochondrial intermembrane space (IMS) (Singh
et al., 2019), and ferroptosis, involving iron-dependent lipid
peroxidation (Conrad et al., 2021). Mitochondrially-mediated
apoptosis plays a fundamental role in embryonic development
(Ke et al., 2018), as well as in the removal of damaged (Aubrey
et al., 2018) or unwanted (Perez-Figueroa et al., 2021) cells
throughout the lifespan of humans. Conversely, resistance to
mitochondrial apoptosis is a hallmark of cancer (Hanahan
and Weinberg, 2011), and an important mediator of treatment
resistance (Carneiro and El-Deiry, 2020).
There are important tissue-specific and pathway-specific
differences in the degree to which mitochondrial functions
contribute to cancer. For example, in silico analysis of
transcriptomic data from multiple tumor types identified that
mitochondrial OXPHOS genes were upregulated in 35% of
cancer types, but downregulated in a further 25% (Gaude
and Frezza, 2016), including clear cell renal cell carcinoma
(ccRCC). Indeed, the downregulation of oxygen consumption
rate (OCR) and OXPHOS is a well-characterized feature of
VHL inactivated ccRCC cells, and is partially buffered by the
metabolic rewiring of ccRCC cells by constitutive activation
of the hypoxia-inducible factor (HIF) pathway (Nilsson et al.,
2015; Briston et al., 2018). Furthermore, mutations in the
TCA cycle genes IDH1/2, FH, and subunits A-D of succinate
dehydrogenase (SDH), are driver mutations in certain cancers,
including renal cancers and gliomas (Han et al., 2020; Yong
et al., 2020). Interestingly, mutations in these genes leads
to the intracellular accumulation of oncometabolites (i.e., 2-
hydroxyglutarate, fumarate, and succinate), which drive disease
progression through their effects on multiple pathways, such as
DNA methylation and the HIF pathway (Han et al., 2020; Yong
et al., 2020).
Thus, while normal mitochondrial functions can support the
development and progression of many cancers, these effects
are not universal, either across cancers or across mitochondrial
functions. A comprehensive review of the contributions of
different mitochondrial functions to cancer is beyond the scope
of this mini-review, and can be found elsewhere (Wallace, 2012;
Vyas et al., 2016).
ESSENTIAL MITOCHONDRIAL GENES
Much has been uncovered regarding the importance of
mitochondria to cancer biology in small-scale (single
gene/cancer) studies (reviewed in Wallace, 2012; Vyas et al.,
2016). However, it is clear that both the multi-gene complexity of
mitochondrial metabolism, and the importance of interactions
between mitochondria and the cellular context (e.g., oncogenic
mutations, microenvironmental conditions) necessitate more
comprehensive efforts to fully understand the importance of
mitochondrial genes in cancer. The advent of genome-wide
CRISPR-Cas9 deletion screening techniques (Evers et al., 2016)
has allowed such comprehensive identification of NEMGs that
are absolutely required for the viability of cultured cancer cells—
genes which can therefore be described as essential. It should be
noted however that, as yet, the published genome-wide CRISPR-
Cas9 single guide (sg)RNA libraries do not contain sgRNAs
that target genes within the mitochondrial genome (mtDNA).
CRISPR-Cas9 targeting of mtDNA has been challenging due to
a lack of recognition sites for the Cas9 enzyme, and the poor
delivery of sgRNA into mitochondria. However, recent studies
have described the generation of gene-editing systems that can be
used for targeting mitochondrially-encoded mitochondrial genes
(MEMGs) (Mok et al., 2020; Hussain et al., 2021). It is clear from
both ethidium bromide and enzymatic depletion of mtDNA in
cancer cells, that MEMGs are also required for the proliferation
of many cancer cell lines (Herst et al., 2004; Kukat et al., 2008).
Several studies have investigated the mutation landscape of
mtDNA in cancer, and have found that loss-of-function mtDNA
mutations are among the most frequent genetic events in cancer
cells, at a rate comparable to many common cancer driver genes
(Gorelick et al., 2021). Interestingly, however, these mutations
were found in two independent studies to be enriched in
subunits of respiratory complex (C)I, but depleted from subunits
of CV (ATPase), suggesting differing contributions of each
respiratory complex to cancer cell viability (Yuan et al., 2020;
Gorelick et al., 2021). Furthermore, loss-of-function mutations
in mtDNA-encoded CI genes were found to be specifically
enriched in cancers of the kidney, colon, and thyroid (Hopkins
et al., 2017; Yuan et al., 2020; Gorelick et al., 2021), highlighting
that tissue etiology is a central determinant of the importance of
mitochondria to cancer development and progression.
A systematic effort to identify genetic dependencies in cancer
cell lines under standard culture conditions is being carried
out by the Achilles project, also known as the Dependency
Map (DepMap) consortium (Tsherniak et al., 2017). Using data
from this project, a functional annotation of all 1158 nuclear-
encoded genes that encode mitochondrially-localized proteins
(Calvo et al., 2016) has been performed recently (Thomas et al.,
2021). These analyses identified that 23.2% (264) of NEMGs are
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essential for the growth of over 90% of the 625 tumor cell lines
tested by DepMap, which are therefore referred to as common
essential genes. It was also shown that NEMGs are enriched
for common essential genes relative to the genome as a whole
(Thomas et al., 2021). Functional annotation of the 264 essential
NEMGs confirmed many of the previously identified genes and
pathways that are important for cancer cell viability (as outlined
in section “Mitochondria and Cancer”) (Figure 1). These include
genes involved in: OXPHOS (e.g., NDUFA2, CYCS); the TCA
cycle (e.g., SDHC, PC); lipid metabolism (e.g., ABCB10, PTPM1);
nucleotide metabolism (e.g., DHODH); amino acid metabolism
(e.g., PRODH, PRODH2); calcium transport (e.g., LETM1); ROS
production and detoxification (e.g., ROMO1, SOD1); apoptosis
(e.g., BCL2L1). Furthermore, common essential NEMGs were
also identified from pathways that have not been previously
characterized as being required for the viability of cancer
cells, such as carbonic acid metabolism (CA5A), and phosphate
metabolism (PPA2, SLC25A3) (Figure 1).
Many of these essential NEMGs have also been identified in
other studies where single cell line genome-wide CRISPR-Cas9
deletion screens have been undertaken, using different cancer
cell lines (Arroyo et al., 2016; Jain et al., 2016; Bao et al., 2021;
Niu et al., 2021; Thomas et al., 2021). Interestingly, while there
is broad pathway-level agreement between these independent
studies, there is little gene-to-gene agreement, and in some cases,
gene hits identified from the CRISPR-Cas9 deletion screen could
not be verified in validation experiments using the primary
screening cell line or additional cell lines (Jain et al., 2020).
Thus, while CRISPR-Cas9 deletion screens of this kind are
powerful tools in determining gene essentiality, care must be
taken when comparing between studies, due to factors such
as the methodological differences in culturing conditions, the
sgRNA library used, and the cell line(s) selected for the screen.
Indeed, the DepMap study clearly demonstrates that specific
gene-to-gene essentiality—including NEMGs—can vary greatly
across cancer cell lines, and even between cell lines with similar
tissue etiologies (Tsherniak et al., 2017). Beyond the importance
of genetic context to the essentiality of NEMGs and pathways,
the metabolic environment has also been shown to significantly





The DepMap project (Tsherniak et al., 2017), and other
independent genome-wide CRISPR-Cas9 deletion screens (e.g.,
To et al., 2019), constitute powerful resources for understanding
gene essentiality in cancer cells. However, only a few screens
use culture conditions that reflect features of the (solid) tumor
microenvironment (TME) (Arroyo et al., 2016; Jain et al., 2020;
Bao et al., 2021; Niu et al., 2021; Thomas et al., 2021). The TME
is central to promoting tumorigenesis and disease progression,
and comprises features that are distinct from surrounding normal
tissue (Egeblad et al., 2010; Elia and Haigis, 2021). Along with
tumor cells, the TME is a multicellular compartment which
includes infiltrating immune cells, has high extracellular matrix
density, and poor vascular perfusion which limits both nutrient
(e.g., glucose) and oxygen availability. Low oxygen levels, known
as hypoxia, is a common feature of the TME, and is associated
with treatment resistance (Begg and Tavassoli, 2020), as well
as poor prognosis in patients (Choudhry and Harris, 2018). As
the major site of oxygen consumption in the cell, mitochondria
are profoundly influenced by the availability of cellular oxygen,
and carbon sources such as glucose, which provide reducing
equivalents for OXPHOS (Thomas and Ashcroft, 2019).
To mimic conditions of the TME, several recent genome-
wide CRISPR-Cas9 deletion screens have been carried out under
conditions of hypoxia (Jain et al., 2020; Bao et al., 2021; Niu
et al., 2021; Thomas et al., 2021), or glucose deprivation (Arroyo
et al., 2016; Thomas et al., 2021), using different cancer cell
types. Importantly, while there are differences in the essentiality
of specific genes identified between studies, there is broad
agreement in the findings across these studies showing that the
essentiality of both non-mitochondrial and mitochondrial genes
is dependent on the environmental context in which cells are
cultured (Figure 2). For example, in two studies it was found that
the deletion of numerous genes involved in OXPHOS improved
the viability of tumor cells cultured in hypoxia (Jain et al.,
2020; Thomas et al., 2021). Interestingly, these genes included
a subset of genes that were found to be essential for tumor
cell viability under standard culture conditions (normoxia and
glucose), such as subunits of respiratory complexes complex
I (e.g., NDUFA8) and complex II (e.g., SDHC), and enzymes
involved in the ubiquinone synthesis pathway (e.g., COQ7),
or clearing mitochondrial ROS (e.g., SOD2) (Figure 2). These
findings are perhaps not surprising, as a reduction in overall
OCR, and a suppression of mitochondrial biogenesis and
protein expression are well-characterized cellular responses to
hypoxia, that are mediated in part through the HIF pathway
(Thomas and Ashcroft, 2019).
Moreover, in the study by Bao and colleagues, the gene
PTPMT1—a NEMG that is required for synthesis of the
essential mitochondrial membrane lipid cardiolipin (Figure 1)—
was discovered to become significantly more essential for the
growth of MHCC97L hepatocellular carcinoma (HCC) cells in
hypoxia (Bao et al., 2021; Figure 2). Interestingly, deletion
of PTPMT1 decreased cellular cardiolipin content, and led to
significantly increased intracellular ROS levels in hypoxia (Bao
et al., 2021). Thus, mitochondrial cardiolipin synthesis appears
to support HCC cell survival in hypoxia, through mitigation of
the cytotoxic effects of ROS production, which is elevated in
hypoxia (Thomas and Ashcroft, 2019; Bao et al., 2021). Notably
however, PTPMT1 was identified as a common essential gene
in normoxia (Tsherniak et al., 2017; Thomas et al., 2021), and
was not found to be significantly more or less essential in other
hypoxia CRISPR-Cas9 deletion screens (Jain et al., 2020; Thomas
et al., 2021). This again highlights that mitochondrial (and non-
mitochondrial) gene essentiality is also dependent on cell type,
and methodological differences between CRISPR-Cas9 deletion
studies must be taken into account when comparing datasets.
Related to this, while the genes encoding the HIF pathway
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FIGURE 1 | Essential NEMGs and their mitochondrial pathway function. Model shows selected NEMGs identified as common essential genes by the DepMap
project, and other genome-wide CRISPR-Cas9 deletion screens of cancer cell lines (Arroyo et al., 2016; Tsherniak et al., 2017; Bao et al., 2021; Thomas et al.,
2021). For a more comprehensive list of common essential NEMGs (see Thomas et al., 2021). Selected common essential NEMGs are denoted in capital letters and
italics. Black arrows denote transport/movement/relationship. Red arrows and red text denote biochemical reactions. Multiple arrow heads denote multiple reactions.
I, respiratory complex I; II, respiratory complex II; III, respiratory complex III, IV, respiratory complex IV; V, respiratory complex V; CoQ, Coenzyme Q; c, cytochrome c;
PA, phosphatidic acid; CL, cardiolipin; mtDNA, mitochondrial DNA; IMS, intermembrane space; ROS; reactive oxygen species; PPi, inorganic pyrophosphate.
proteins HIF-1α (HIF1A) and HIF1-β (ARNT) were found to
be the two most essential for hypoxic survival in MHCC97L
(HCC) cells (Bao et al., 2021), no HIF pathway genes were among
the most essential genes identified from CRISPR-Cas9 deletion
screens using K562 chronic myeloid leukemia cells (Jain et al.,
2020), or U2OS osteosarcoma cells (Thomas et al., 2021).
While specific NEMGs were shown to be less essential in
hypoxia compared to normoxia, in contrast their essentiality
increased in cells cultured in the absence of glucose (and
substitution with galactose) (Arroyo et al., 2016; Thomas et al.,
2021; Figure 2). Galactose, like glucose, can be metabolized
to pyruvate to support OXPHOS. Unlike the metabolism of
glucose to pyruvate in glycolysis, metabolism of galactose to
pyruvate produces no net ATP (Rossignol et al., 2004), and
increases the reliance of cells on OXPHOS for bioenergetic
homeostasis, and thus cells become more sensitive to inhibitors
of the respiratory chain (Marroquin et al., 2007). In agreement,
a large number of the differentially essential genes identified
in both the Arroyo et al. and Thomas et al. independent
genome-wide CRISPR deletion screens in galactose, were found
to be genes that encode respiratory complex subunits (e.g.,
NDUFA6), and OXPHOS accessory proteins, such as those
involved in Fe/S cluster formation (e.g., IBA57, NFU1), and
the ubiquinone synthesis pathway (COQ7) (Figure 2). Another
large subset of essential NEMGs in galactose were found to
be related to maintenance and regulation of expression of
genes from mtDNA, such as MRPS6 and YBEY (Figure 2).
Beyond OXPHOS, NEMGs from numerous other mitochondrial
pathways were also more essential in galactose in both studies
(Arroyo et al., 2016; Thomas et al., 2021), including genes
involved in fatty acid metabolism (MCAT) and the TCA cycle
(e.g., MDH2). These studies clearly highlight the importance
of the metabolic context for mitochondrial gene essentiality in
cancer cells, but it should be noted that galactose substitution
of glucose in culture may not entirely recapitulate the effects
of glucose deprivation found in the TME or fully mimic the
effects of metabolic reprogramming of glucose in cancer cells
(Hay, 2016).
THERAPEUTIC IMPLICATIONS
In cancer, hypoxia and dysregulated mitochondrial metabolism
are key features of (solid) tumors, and are associated with
metabolic reprogramming and disease progression (Weinberg
and Chandel, 2015; Thomas and Ashcroft, 2019; Frattaruolo et al.,
2020). Tumor cells rely on both glycolysis and OXPHOS to
survive, and thus OXPHOS has become an increasingly attractive
area for therapeutic exploitation in cancer (Molina et al., 2018;
Shi et al., 2019; Vasan et al., 2020). Of particular interest, from
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FIGURE 2 | Contextual essentiality of mitochondrial genes. Model shows NEMGs identified from genome-wide CRISPR-Cas9 deletion screens of cancer cell lines,
shown to be selectively essential under specific cancer cell culture conditions [hypoxia, normoxia, glucose and glucose-free (galactose)]. Studies included are
indicated as follows: 1 (Thomas et al., 2021); 2 (Jain et al., 2020); 3 (Arroyo et al., 2016); 4 (Bao et al., 2021). Red highlighted genes were identified as common
essential under standard culture conditions by the DepMap Project (Tsherniak et al., 2017).
a safety perspective, is the use of drug repurposing which
has identified OXPHOS inhibitors with anti-tumor activity
(Pernicova and Korbonits, 2014; Ashton et al., 2016; Aminzadeh-
Gohari et al., 2020; Zhang et al., 2020). Furthermore, while
the lethality of glucose deprivation for many cultured cancer
cells constitutes a significant technical challenge when carrying
out CRISPR-Cas9 deletion screens under this condition, the
findings from such screens (Arroyo et al., 2016; Thomas
et al., 2021) provide valuable insight into targeting glucose
metabolism in cancer as a potential therapeutic strategy (Hay,
2016). Given the importance of mitochondria for normal
physiological processes, delineating how mitochondrial gene
function underlies tumorigenesis, and in the context of hypoxia,
will be vital for understanding the potential therapeutic benefit of
exploiting mitochondrial function(s) in cancer.
Finally, outwith cancer, the findings from CRISPR-Cas9
deletion screens and other studies (Arroyo et al., 2016;
Jain et al., 2016; Thomas et al., 2021) have important therapeutic
implications for mitochondrial disease, as they show that hypoxia
promotes survival and can protect cells from the potentially
deleterious effects of mitochondrial gene mutation and loss of
function. Whether hypoxia could provide therapeutic benefit
clinically in mitochondrial disease (Jain et al., 2016), or offer a
means to strategically reveal drug-induced mitochondrial toxicity
of novel therapeutic agents as part of the preclinical drug
development path, is of intense interest and has yet to be realized.
CONCLUSION
Mitochondria are key metabolic and signaling hubs in eukaryotic
cells, and are the site of numerous biochemical pathways
that support cell viability. A growing body of evidence has
demonstrated that the importance of mitochondrial functions for
cell viability can vary depending on the genetic and metabolic
context. Recently, genome-wide CRISPR-Cas9 deletion screens
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have allowed for the identification of individual mitochondrial
(and non-mitochondrial) genes that are essential for the viability
of cancer cell lines, under different tumor-relevant conditions.
These approaches have revealed important insights into the
contextual nature of mitochondrial gene essentiality in cancer
cells, and provide a unique resource of potential therapeutic
targets for further investigation and exploitation. Interestingly,
genome-wide CRISPR screens are also being applied for target
deconvolution in drug development studies (Neggers et al., 2018),
and their future applications may allow for the identification of
genes underlying disease-relevant phenotypes other than viability
(e.g., migration).
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